NovaBay Pharmaceuticals will attend Annual LD MICRO Conference

By December 1, 2014

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will be attending the LD MICRO Conference on Wednesday & Thursday, December 3-4, 2014, at the Luxe Sunset Boulevard Hotel in Los Angeles.

LD Micro a by-invitation-only newsletter firm that focuses on finding undervalued micro-cap companies.

To arrange a meeting with management, please contact Jane Edmonds at: 510-899-8851.

About NovaBay Pharmaceuticals, Inc.:
Going Beyond Antibiotics®?NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: Aganocide® compounds, led by auriclosene, and its Neutrox family of products, led by Advanced i-Lid™ Cleanser for the eye care market, NeutroPhase® for wound care, and CelleRx™  for the dermatology market. To learn more about Aganocides and Neutrox family of product, please see the video presentation by Dr. Keith Bley and our recently published white paper.

Stay informed on NovaBay’s progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
Download our Free Mobile Investor App from the Apple Store or Google Play.

NovaBay Contacts

For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact T. Paulson